Medical Stock Shows Strength In A Weakening Market; Nears Buy PointInvestors Business Daily • 09/01/22
Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to BuyZacks Investment Research • 08/08/22
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional StockBusiness Wire • 08/05/22
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable NeurostimulatorBusiness Wire • 05/31/22
Axonics: A Strong Medical Device Play With Significant Revenue Growth OpportunitiesSeeking Alpha • 05/30/22
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22
Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/28/22
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation SystemBusiness Wire • 04/19/22
Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation SystemBusiness Wire • 03/07/22
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/25/22